Home / Stocks / Sun Pharma Adv.res.co.ltd
SPARC

Sun Pharma Adv.res.co.ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹192.57

Change

+2.45 (1.29%)

Open

₹190.65

Prev. Close

₹190.12

Day High

₹194.26

Day Low

₹188.1

Volume Analysis

Traded

606,222

Delivered

210,313

Delivery %

34.69%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (279.0%)
  • •Strong operating margin (85.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year revenue growth (98.8%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹201.34 ₹197.8 ₹195.18 ₹191.64 ₹189.02 ₹185.48 ₹182.86
Fibonacci ₹197.8 ₹195.45 ₹193.99 ₹191.64 ₹189.29 ₹187.83 ₹185.48
Camarilla ₹194.26 ₹193.7 ₹193.13 ₹191.64 ₹192.01 ₹191.44 ₹190.88

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+42.61%

1 Week

-9.31%

1 Month

+7.42%

3 Months

-2.1%

6 Months

-8.2%

1 Year

+39.48%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹218.66

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

110.02%

Net margin 84.68% × asset turnover 1.12x × equity multiplier 1.16x

Company Overview

Sector

Healthcare

Market Cap

₹6,680 Cr

P/E (TTM)

4.05

ROE

279.0%

Book Value

₹44.4

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Sun Pharma Adv.res.co.ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (23/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (279.0%); strong operating margin (85.0%). Strong 3-year revenue growth (98.8%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

45

Cash Flow

32

Corporate Governance

56

Momentum

54

Institutional Ownership

23

Business Quality

100

Risk & Volatility

29

Liquidity

43

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • −Stock is trading at 4.63 times its book value
  • −Working capital days have increased from -768 days to 215 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

NSE and BSE grant reclassification approval for Krishna, Sudhir and Raksha Valia from promoter group to public.

SPARC confirms compliance and denies any undisclosed information behind volume increase.

Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume.

Newspaper Advertisement for Publication of Financial Results

Monitoring agency report for Q2 FY27 shows no deviation in warrant proceeds; 150 Cr utilized.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 21 14 17 17 13 15 27 10 8 8 1,853 40 30
Expenses + 113 116 122 110 116 89 80 62 74 65 80 74 76
Operating Profit -91 -103 -106 -93 -103 -74 -53 -52 -66 -57 1,773 -34 -46
OPM % -432.0% -740.0% -639.0% -555.0% -800.0% -494.0% -196.0% -540.0% -836.0% -670.0% 96.0% -85.0% -152.0%
Other Income + 8 6 4 2 0 0 0 9 0 -12 2 24 24
Interest 0 0 1 1 1 3 5 6 8 9 12 8 0
Depreciation 3 3 3 3 3 3 3 3 3 3 2 2 2
Profit before tax -86 -100 -105 -96 -107 -79 -61 -52 -76 -80 1,761 -21 -24
Tax % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.0%
Net Profit + -86 -100 -106 -96 -107 -80 -60 -52 -76 -80 1,761 -21 -24
EPS in Rs -3 -3 -3 -3 -3 -2 -2 -2 -2 -2 54 -1 -1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — -65 -30 -39 8 64 -43 -39 -43 6,716 314 282

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 239 76 72 1,879 1,932
Expenses + 453 478 395 280 295
Operating Profit -214 -402 -323 1,599 1,637
OPM % -90.0% -532.0% -450.0% 85.0% 85.0%
Other Income + 11 29 2 -2 37
Interest 8 2 9 34 29
Depreciation 12 13 12 10 9
Profit before tax -223 -387 -343 1,553 1,636
Tax % 0.0% 0.0% 0.0% 0.0% —
Net Profit + -223 -387 -343 1,553 1,636
EPS in Rs -7 -12 -11 48 50
Dividend Payout % 0.0% 0.0% 0.0% 0.0% —
Sales growth — -68 -5 2,518 3,141

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 480 93 -249 1,306 1,410
Borrowings + 16 61 269 559 2
Other Liabilities + 302 328 284 273 229
Total Liabilities 830 515 336 2,171 1,674
Fixed Assets + 106 108 99 85 153
CWIP 27 44 54 72 3
Investments 291 2 0 0 239
Other Assets + 406 362 183 2,014 1,279
Total Assets 830 515 336 2,171 1,674
Equity Capital 32 32 32 32 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -69 -429 -360 -239
Cash from Investing Activity + -548 392 158 -23
Cash from Financing Activity + 617 42 199 261
Net Cash Flow -1 5 -3 -1
Free Cash Flow -84 -455 -370 -262
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 35 106 114 -17

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 65.68% → 65.68%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 30.36% 30.41% 31.51% 31.96% 31.47% 31.76% 31.88% 31.52% 31.51% 31.41% 30.34% 30.48%
Promoters 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.67% 65.67% 65.67% 65.67% 65.68% 65.68%
FII 3.3% 3.24% 2.64% 2.15% 2.23% 1.45% 1.47% 1.76% 2.04% 2.04% 3.9% 3.74%
DII 0.67% 0.67% 0.17% 0.21% 0.64% 1.13% 0.97% 1.05% 0.78% 0.88% 0.09% 0.11%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sun Pharma Adv.res.co.ltd (this stock) 6,680 4.05 4.64 279.0%
Nephrocare Health Serv L 6,500 50.8 5.46 8.83%
Bliss Gvs Pharma Ltd 7,075 43.5 5.5 11.8%
Kovai Medical Center & Ho 7,108 123.0 24.58 22.2%
Fdc Limited 6,177 18.8 2.31 11.5%
Innova Captab Limited 5,938 35.6 5.09 13.7%
Sanofi India Limited 7,603 17.2 8.83 47.1%

Which Mutual Funds Hold Sun Pharma Adv.res.co.ltd?

Frequently Asked Questions about Sun Pharma Adv.res.co.ltd

Community Sentiment

What are other investors saying about Sun Pharma Adv.res.co.ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.